medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2021, Number 3

<< Back Next >>

Rev Mex Urol 2021; 81 (3)

Review of the application of photoselective vaporization in benign hyperplasia of the prostate

Arana-Carrera AL, Morales-Ramos VM

Language: Spanish
References: 32
Page: 1-13
PDF size: 228.92 Kb.


ABSTRACT

Benign prostatic hyperplasia is the most frequent benign tumor in men, reaching a prevalence of 40% in the fourth decade of life and 80% in men 80 years of age and older. The condition leads to bothersome and incapacitating lower urinary tract symptoms that are currently measured by the International Prostate Symptom Score. At present, there are different alternatives for minimally invasive surgical treatment, such as GreenLight laser photoselective vaporization, that can provide the same benefits for the patient as conventional treatment options.
Methods: To find out and describe the usefulness and safety of photoselective vaporization in patients with benign prostatic hyperplasia, a search for information published within the last 10 years was conducted on the PubMed, ScienceDirect, BVS, and ClinicalKey databases, resulting in the selection of 11 notable studies.
Conclusion: GreenLight laser photoselective vaporization is a safe and efficacious alternative for managing the symptoms of benign prostatic hyperplasia, in the short term and long term, with a lower risk of complications than transurethral resection of the prostate.


REFERENCES

  1. Madersbacher S, Sampson N, Culig Z. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini- Review. Gerontology. 2019;65(5):458–64. doi: 10.1159/000496289

  2. Castro-Díaz D, Díaz-Cuervo H, Pérez M. Hiperplasia benigna de próstata y su tratamiento: impacto en calidad de vida y función sexual. Actas Urol Esp. 2013;37(4):233–41. doi: 10.1016/j.acuro.2012.08.001

  3. Robledo XG, Perdomo HAG. Mecanismos inflamatorios involucrados en la fisiopatología de la hiperplasia prostática benigna. Urología colombiana. 2020;29(4):240:4.

  4. Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010;5(4):212–8. doi: 10.1007/ s11884-010-0067-2

  5. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367(3):248–57. doi: 10.1056/NEJMcp1106637

  6. Lee HW, Kim SA, Nam JW, Kim MK, Choi BY, Moon HS. The study about physical activity for subjects with prevention of benign prostate hyperplasia. Int Neurourol J. 2014;18(3):155– 62. doi: 10.5213/inj.2014.18.3.155

  7. Sausville J, Naslund M. Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians. Int J Clin Pract. 2010;64(13):1740–5. doi: 10.1111/j.1742- 1241.2010.02534.x

  8. Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012;19 Suppl 1:10–7.

  9. Homma Y, Gotoh M, Yokoyama O, Masumori N, Kawauchi A, Yamanishi T, et al. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011;18(11):741–56. doi: 10.1111/j.1442-2042.2011.02860.x

  10. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015;22 Suppl 1:1–6.

  11. Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020;204(4):799–804. doi: 10.1097/ JU.0000000000001298

  12. Andrés G, Arance I, Gimbernat H, Redondo C, García-Tello A, Angulo JC. Laser transurethral resection of the prostate: Safety study of a novel system of photoselective vaporization with high power diode laser in prostates larger than 80mL. Actas Urol Esp. 2015;39(6):375–82. doi: 10.1016/j.acuro.2014.10.007

  13. Rodríguez Reina G, Vázquez Alba D, Martínez-Salamanca JI, Carballido Rodríguez J. Hiperplasia benigna de próstata. Medicine. 2011;10(83):5628–41.

  14. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37. doi: 10.1016/j.eururo.2013.09.046

  15. Sountoulides P, Kaufmann O, Kikidakis D, Pardalidis N. Vaporización fotoselectiva de la próstata (VFP) vs enucleacion de la próstata con láser holmio (HOLEP): resultados actuales y estrategias. Archivos Españoles de Urología. 2010;63(2):89–101.

  16. Malek RS, Barrett DM, Kuntzman RS. Highpower potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998;51(2):254–6. doi: 10.1016/ s0090-4295(97)00613-4

  17. Kuromatsu I, Imamura T, Sugimura Y. [Photoselective vaporization of the prostate (PVP) using 80 watt high power potassiumtitanyl- phosphate (KTP) laser for benign prostatic hyperplasia: the first fifty-seven patients in Japan]. Nihon Hinyokika Gakkai Zasshi. 2006;97(7):815–22. doi: 10.5980/ jpnjurol1989.97.815

  18. Woo H, Reich O, Bachmann A, Choi B, Collins E, Rosette J de la, et al. Outcome of GreenLight HPS 120-W Laser Therapy in Specific Patient Populations: Those in Retention, on Anticoagulants, and with Large Prostates (≥ 80 ml). European Urology Supplements. 2008;7(4):378–83. doi: 10.1016/j. eursup.2008.01.016

  19. Zhou Y, Xue B, Mohammad NA, Chen D, Sun X, Yang J, et al. Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci. 2016;31(3):485–95. doi: 10.1007/s10103-016- 1895-x

  20. Bachmann A, Muir GH, Collins EJ, Choi BB, Tabatabaei S, Reich OM, et al. 180-W XPS GreenLight laser therapy for benign prostate hyperplasia: early safety, efficacy, and perioperative outcome after 201 procedures. Eur Urol. 2012;61(3):600–7. doi: 10.1016/j. eururo.2011.11.041

  21. NICE Guidance. GreenLight XPS for treating benign prostatic hyperplasia: © NICE (2016) GreenLight XPS for treating benign prostatic hyperplasia. BJU Int. 2017;119(6):823–30. doi: 10.1111/bju.13897

  22. Ajib K, Mansour M, Zanaty M, Alnazari M, Hueber P-A, Meskawi M, et al. Photoselective vaporization of the prostate with the 180-W XPS-Greenlight laser: Five-year experience of safety, efficiency, and functional outcomes. Can Urol Assoc J. 2018;12(7):E318–24. doi: 10.5489/cuaj.4895

  23. Piotrowicz G, Syryło T, Jedynak R, Zieliński H. Efficacy and Safety of Photoselective Vaporization of the Prostate with 120 W 532 nm Laser in Patients with Benign Prostatic Hyperplasia on Anticoagulation or Antiplatelet Therapy: Observations on Long-Term Outcomes. Photomed Laser Surg. 2018;36(5):273–83. doi: 10.1089/pho.2017.4367

  24. Meskawi M, Hueber P-A, Valdivieso R, Bruyere F, Misrai V, Fournier G, et al. Multicenter international experience of 532 nm-laser photovaporization with Greenlight XPS in men with large prostates (prostate volume > 100 cc). World J Urol. 2017;35(10):1603–9. doi: 10.1007/s00345-017-2007-7

  25. Valdivieso R, Hueber P-A, Meskawi M, Belleville E, Ajib K, Bruyere F, et al. Multicentre international experience of 532-nm laser photoselective vaporization with GreenLight XPS in men with very large prostates. BJU Int. 2018;122(5):873–8. doi: 10.1111/bju.14208

  26. Castellani D, Cindolo L, Nunzio CD, Rosa MD, Greco F, Gasparri L, et al. Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis. Urology. 2018;121:147–52. doi: 10.1016/j.urology.2018.09.007

  27. Peng L, Zheng X-N, Wu J-P, Zeng X, He Q, Chen G, et al. Holmium laser technologies versus photoselective greenlight vaporization for patients with benign prostatichyperplasia: a meta-analysis. Lasers Med Sci. 2020;35(7):1441– 50. doi: 10.1007/s10103-020-02953-z

  28. Zang Yc, Deng Xx, Yang Dr, Xue Bx, Xu Lj, Xl L, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis of randomized controlled trials. Lasers Med Sci. 2015;31(2):235–40. doi: 10.1007/s10103-015-1843-1

  29. Thomas JA, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol. 2016;69(1):94–102. doi: 10.1016/j.eururo.2015.07.054

  30. Cornu J-N, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol. 2015;67(6):1066–96. doi: 10.1016/j.eururo.2014.06.017

  31. Lai S, Peng P, Diao T, Hou H, Wang X, Zhang W, et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: an updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open. 2019 Aug 21;9(8):e028855. doi: 10.1136/ bmjopen-2018-028855.

  32. Vasudeva P, Kumar N, Kumar A, Kumar G, Patel M, Gupta P. Impact of monopolar TURP, bipolar TURP and photoselective vaporization of prostate for enlarged prostate on erectile function. Low Urin Tract Symptoms. 2019 Jan;11(1):24–9. doi: 10.1111/luts.12189




2020     |     www.medigraphic.com